QuickView for complement component C5a binding (biogroup)

1. L1000 CMAP Prostate cancer VCaP cells with gene overexpression perturbations
2. Time course profile of umbilical cord blood cells in culture
3. L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (1 of 2)
4. L1000 CMAP - Carcinoma of prostate PC3 cells treated with ligand perturbagens
5. SWNCT and MWCNT vs. asbestos subchronic exposures to human small airway epithelial cells

There were no matches for complement component C5a binding

1. First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
2. A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Fede…
3. Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®
4. The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
5. JET-GBS - Japanese Eculizumab Trial for GBS